Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536

epoetin alfa
vasectomy
erythropoietin
cancer
  • 53 views
  • 26 Mar, 2021
  • 7 locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US  

luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.   The

epoetin alfa
vasectomy
erythropoietin
cancer
  • 5134 views
  • 19 Apr, 2021
  • 15 locations
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects: Subjects receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the …

hysterectomy
luspatercept
ace-536
cancer
growth factor
  • 82 views
  • 27 Jan, 2021
  • 125 locations
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided …

  • 0 views
  • 05 May, 2021
  • 156 locations
Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Na ve Subjects Who Require Red Blood Cell Transfusions

Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536

cancer
anemia
blood transfusion
bone marrow procedure
erythropoietin
  • 289 views
  • 18 Apr, 2021
  • 259 locations
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Practice (GCP) and applicable regulatory requirements. This is a Phase 2, multicenter, single-arm study to evaluate the efficacy, safety and Pharmacokinetics (PK) of luspatercept (ACE-536) for the

anemia
bone marrow procedure
blood transfusion
cancer
  • 0 views
  • 18 Mar, 2021
  • 15 locations